Investing.com -- Abbott Laboratories (NYSE:ABT) said Friday that it could restart its Sturgis, Michigan plant within two weeks, pending FDA approval.
In February, Abbott recalled three baby-formula products after reports of infant illness, including two infants who died.
Abbott is one of the biggest baby formula suppliers in the U.S. and the recall has fueled an industry-wide baby formula shortage.
According to a report from Bloomberg, during a routine visit to Abbott’s Sturgis, Michigan, manufacturing facility in September, FDA inspectors "determined that employees may have transferred contaminants including deadly cronobacter from surfaces to baby formula."
However, Abbott has denied its formula is to blame, with the company telling Bloomberg that "There is no evidence to link our formulas to these infant illnesses.”
In a statement today, Abbott said it is working to address an FDA list of observations so it can restart the Sturgis, Michigan facility.
"Subject to FDA approval, we could restart the site within two weeks," Abbott stated.